Summary:
Phase 1, Open label, nonrandomized, single dose study to investigate the safety, tolerability, and pharmacokinetics of MRTX849
Qualified Participants Must:
• Male or Female
• Age 18 to 75 years old
• BMI 18 to 40
• have been diagnosed with liver disease, have a liver impairment, or a condition involving the liver
• avaliable for a 8 day, 7 night stay at the Research Center